Previous 10 | Next 10 |
Catalyst Pharmaceuticals ([[CPRX]]) reported very strong financial results for 2019’s second quarter, reporting 60% upside to the analyst consensus revenue estimate , also driving the company into profitable territory. We were a bit surprised with the muted reaction to the earnings pri...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. In...
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2019 Earnings Conference Call August 8, 2019 8:30 A.M. ET Company Participants Alicia Grande - Chief Financial Officer Pat McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steve Miller - Chief Operati...
Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q2 GAAP EPS of $0.10 beats by $0.07 . More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla., Aug. 07, 2019 (GLOBE NEWSWIRE)...
AAOI , AGO , AIG , ALB , AMPH , ANGI , ARNA , ASRT , ATO , AVLR , AZPN , BKNG , BREW , CABO , CAI , CCMP , CDE , CECO , CLI , COLL , CPA , CPRX , CSGS , CTL , CVNA , CWH , DAR , DOX , DVAX , EB , ECPG , ENS , ENV , ET , EVRG , FG , FLO , FNV , FOSL , ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...
CORAL GABLES, Fla., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
CORAL GABLES, Fla., July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...